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Abstract
MicroRNAs (miRs) are small, non-protein coding transcripts involved in many cellular functions. Many miRs have emerged as
important cancer biomarkers. In the present study, we investigated whether miR levels in breast tumors are predictive of
breast cancer local recurrence (LR). Sixty-eight women who were diagnosed with breast cancer at the Lombardi
Comprehensive Cancer Center were included in this study. Breast cancer patients with LR and those without LR were
matched on year of surgery, age at diagnosis, and type of surgery. Candidate miRs were identified by screening the
expression levels of 754 human miRs using miR arrays in 16 breast tumor samples from 8 cases with LR and 8 cases without
LR. Eight candidate miRs that showed significant differences between tumors with and without LR were further verified in
52 tumor samples using real-time PCR. Higher expression of miR-9 was significantly associated with breast cancer LR in all
cases as well as the subset of estrogen receptor (ER) positive cases (p=0.02). The AUCs (Area Under Curve) of receiver
operating characteristic (ROC) curves of miR-9 for all tumors and ER positive tumors are 0.68 (p=0.02) and 0.69 (p=0.02),
respectively. In ER positive cases, Kaplan-Meier analysis showed that patients with lower miR-9 levels had significantly better
10-year LR-free survival (67.9% vs 30.8%, p=0.02). Expression levels of miR-9 and another miR candidate, miR-375, were also
strongly associated with ER status (p,0.001 for both). The potential of miR-9 as a biomarker for LR warrants further
investigation with larger sample size.
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Introduction
Widespread screening strategies through mammography have
led to the detection of breast cancer at early stages with a clear
positive impact on treatment outcome and patient survival [1].
Several treatment options are available for early stage breast
cancer patients, including breast conserving surgery (BCS)
followed by radiation therapy and/or adjuvant systemic therapy
where appropriate [2,3]. However, patients who elect breast
conserving surgical treatments have a higher risk of developing
local recurrence (LR) than patients treated by radical mastectomy
[4]. Moreover, a subset of patients will develop LR despite
receiving radiation therapy [5]. Therefore, the discovery and
characterization of biomarkers for predicting LR could have an
impact on the choice of optimal treatment regimes and clinical
management of breast cancer.
Several factors associated with higher recurrence risk have been
described. Well established risk factors include tumor involved
surgical margins, tumor multicentricity, and younger age at
diagnosis [6–8]. Additional risk factors, albeit with limited
predictive power, have been identified such as a family history
of breast cancer and other tumor characteristics (e.g. extensive
intraductal component, lobular carcinoma, estrogen receptor
negative, lymph node invasion) [9,10]. However, a clear-cut set
of biomarkers that can accurately predict LR is still to be
identified.
Molecular classification of breast cancer based on gene
expression profiling, including with commercially available assays
(OncotypeDX, MammaPrint), has been shown to distinguish
between distinct breast cancer subtypes that have different
prognosis, but their reliability in predicting LR has not been
confirmed [11–16]. Recent studies suggest that molecular classi-
fication based on miR expression profiles is capable of accurately
distinguishing breast cancer subtypes [17,18].
miRs are small non-coding RNA molecules that regulate the
activity of specific mRNA targets, and are involved in a variety of
physiological and pathological processes, including carcinogenesis
[19,20]. Expression profiles for miRs are tissue specific and miRs
appear to be excellent biomarkers for human cancers, including
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39011breast cancer [21,22]. miR profiles in cancer tissue have been
associated with cancer prognosis and with tumor characteristics in
several cancers, including breast cancer [23–25]. Several miRs
have also been shown to be involved in breast cancer metastasis
[26,27]; however no study to date has investigated their role in
predicting breast cancer LR. In this study, we performed miR
profiling and assessed the predictive potential of miR candidate
markers in the tumor tissue of breast cancer patients with and
without LR.
Results
Characteristics of Study Population
The characteristics of the study subjects are presented in
Table 1. There were no significant differences between cases with
and without LR in demographic and clinical factors, such as age at
diagnosis, race, histological type, tumor size, type of surgery, year
of surgery and use of systemic therapy. Cases with LR had higher
percentage of advanced stage (III – IV) disease (18.2% vs.6.6%)
and fewer ER positive tumors (56.5% vs. 80.0%, p=0.05)
compared with those with no recurrence (Table 1).
Identification of miRs Candidates for Predicting Breast
Cancer LR
Eleven out of 754 miRs showed significant differences in
expression between tumors with LR and those without LR at
p,0.05 level. 3 miRs were excluded due to low real-time PCR
success rates (,50%) and 8 miRs were selected from these as
candidates for further validation in expression levels (Table 2).
None of 8 miR candidates showed high correlation (r .0.8) with
any other miR candidates (Table S1).
Association of miR-9 with Breast Cancer LR
The 8 miR candidates selected were analyzed individually using
the entire sample set (23 LR cases and 45 without recurrence);
however, the samples used in the screening were excluded from
statistical analysis in the validation step. The measurements of
miRs in the screening sample set were consistent between the
screening and validation studies, with significant correlation (r
ranged from 0.58 to 0.89, p,0.05) between screening and
validation delta Cts of all miR candidates except miR-758
(r=0.30, p=0.25, data not shown).
miR-9 was the only miR candidate that showed significantly
different expression levels between cases with and without LR
(Table 2). The expression of miR-9 was significantly higher in
tumors from patients with LR compared to tumors from
patients without LR (average fold change =1.26, p=0.0495,
table 2). Distributions of delta Ct values of miR-9 were
compared between cases with and without LR. The median
delta Ct values of miR-9 were 10.24 (range: 3.38 to 15.02) in
cases without LR and 9.60 (range: 4.45 to 11.29, p=0.02) in
cases with LR (Figure 1A). Regarding the potential of miR-9 to
discriminate cases with and without LR, the AUC of ROC
curve of miR-9 was computed to be 0.68 (p=0.02), validating
its value in predicting LR (Figure 1B).
As ER status is strongly associated with miR-9, the association
between miR-9 and LR was further investigated in ER positive
and ER negative cases separately. In ER positive cases, the median
delta Ct values of miR-9 were 11.11 (range: 3.38 to 15.02) in cases
without LR, and 10.04 (range: 5.96 to 11.29) in cases with LR
(p=0.02, Figure 1C). In ER negative cases, the mean delta Ct
values of miR-9 were 7.67 (range: 5.98 to 10.52) in cases without
LR, and 8.00 (range: 4.45 to 10.27) in cases with LR (p=0.93,
Figure 1E). Significant association with LR was observed in ER
positive samples with AUC of ROC curve of 0.69 (p=0.02,
Figure 1D), but not in in ER negative cases (AUC =0.53,
p=0.93, Figure 1F).
When dichotomized using the median expression level in cases
without recurrence, Kaplan-Meier analysis revealed that patients
with low expression levels of miR-9 had better 10-year LR-free
survival than those with high levels. 65.7% of patient with low
miR-9 level did not have LR at 10 years, compared to 44.5% of
patients with high miR-9 level (p=0.08, Figure 2A). When only
ER positive cases were analyzed, the 10-year LR-free survival
between patients with low and high miR-9 levels showed
substantial and statistically significant differences, with 67.9%
10-year LR-free survival rate in patients with low miR-9






Age at diagnosis, mean (SD) 51.1 (13.9) 53.4 (11.4) 0.31
Tumor size in cm, mean (SD) 2.19 (1.17) 1.91 (1.49) 0.14
Months of follow-up,
mean (SD)
83.0 (59.1) 74.7 (53.0) 0.58
Race, N (%) 0.41
White 12 (52.2) 29 (64.5)
Black 6 (26.1) 6 (13.3)
Others 5 (21.7) 10 (22.2)
Histological type 0.65
Ductal carcinoma 20 (87.0) 36 (80.0)
Duct &/or lobular carcinoma 1 (4.3) 6 (13.3)
Others 2 (8.7) 3 (6.7)
Stage, N (%) 0.26
0 - I 5 (23.8) 16 (35.5)
II 12 (57.1) 26 (57.8)
III - IV 4 (19.1) 3 (6.7)
Type of surgery, N (%) 0.35
Lumpectomy 10 (43.5) 17 (37.8)
Partial Mastectomy 6 (30.1) 7 (15.5)
Total mastectomy 7 (30.4) 17 (37.8)
Others 0 4 (8.9)
Year of Surgery, N (%) 0.74
Before 1995 2 (10.0) 5 (13.9)
1995–1999 11 (55.0) 16 (44.4)
After 1999 7 (35.0) 15 (41.7)
Systemic therapy, N (%)
None 4 (17.4) 16 (35.5) 0.34
Radiation therapy only 3 (13.0) 8 (17.8)
Chemotherapy only 6 (26.1) 8 (17.8)
Both 10 (43.5) 13 (28.9)
ER ˆ status, N (%) 0.05
Positive 13 (56.5) 36 (80.0)
Negative 10 (43.5) 9 (20.0)
p-values were based on Wilcoxon rank sum test (continuous variables), chi-
square or Fisher’s exact test (categorical variables) ‘estrogen receptor.
doi:10.1371/journal.pone.0039011.t001
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patients with high miR-9 expression (p=0.02, Figure 2B).
Association of miR-9 and miR-375 with Tumor ER Status
We examined associations between expression levels of miR
candidates and other tumor, clinical, and demographic factors
that were known to be associated with breast cancer LR. miR-9
expression level was significantly associated with ER status
(p,0.001) and clinical stage (p=0.03, Table 3). The mean delta
Ct values of miR-9 were 7.83 (range: 4.45 to 10.52) in ER
negative samples and 10.44 (range: 3.38 to 15.02) in ER
positive samples (Figure 3A). No statistically significant associa-
tions between miR-9 and age at diagnosis, tumor size and
histological type, year and type of surgery, and systemic therapy
were found (Table 3).
Expression level of another miR candidate, miR-375, was found
to be significantly associated with ER status, histological type, type
of surgery and systemic therapy (Table 3). The mean delta Ct
values of miR-375 were 6.79 (range: 2.14 to 14.50) in ER negative
samples and 3.80 (range: 0.27 to 6.83) in ER positive samples
(p,0.001, Figure 3B). Consistent with these results, miR-9 and
2375 showed significant capability of predicting ER status of
patients, with AUCs of 0.78 and 0.81, respectively (p,0.001,
Figure 3C, D).
Discussion
Breast cancer patients undergoing BCS are subjected to the risk
of recurrence of breast cancer as well as the adverse effects caused
by the standard systemic treatment after surgery. Therefore, it is
highly desirable to identify biomarkers that can distinguish patients
with high and low risks of recurrence. We report herein the
discovery of two micro RNAs in breast tumor tissue, miR-9 and
miR-375, which were associated with estrogen receptor status, one
of them (miR-9) was significantly associated with local recurrence
in ER positive tumors. The two miR markers were identified by
a real-time PCR screening of 754 miR expression profiles followed
by validation of selected miRs in 52 breast tumors, among those 16
presented LR and 36 did not.
Although this is the first report associating these miRs with
estrogen receptor and LR in breast cancer, miR-9 and miR-375
have been shown to play important roles in many biological
processes including carcinogenesis at different biological sites.
Under physiologic conditions, miR-9 has been described as having
a role in the development of the nervous system [28] and
hepatocytes [29], and in the negative regulation of the acute
responses of innate immunity [30]. In cell line studies, miR-9 has
been observed to target junction protein E-cadherin, facilitating
metastases and stimulating angiogenesis in breast cancer and HCC
cells [31,32]. Methylation and down-regulation of miR-9 was
frequently observed in colorectal cancer cell lines and primary
CRC tumors and associated with lymph node metastasis [33]. In
addition, miR-9 is involved in the carcinogenesis of biliary tract
carcinoma [34], glioblastoma [35], colorectal cancer [36], Burkitt
lymphoma [37], clear cell renal cell carcinoma [38] and gastric
cancers [39].
miR-375 is generally considered to be a tumor suppressor and
thus is down-regulated in many types of cancers, including
esophageal squamous cell carcinoma [40], head and neck
squamous cell carcinoma [41], Pancreatic cancer [42], melanoma
[43], and Esophageal Cancer [44]. Ectopic expression of miR-375
inhibited melanoma cell proliferation, invasion, and cell motility
[43]. Conversely, ectopic expression of miR-375 is shown to
repress cancer progression in pancreatic cancer [42], melanoma
[43], gastric cancer [45], and liver cancer [46]. However, there are
conflicting reports regarding the association between miR-375
level and cancer prognosis, suggesting a more complex and
possibly cancer specific relationship. It was reported to be
significantly lower in the serum of esophageal squamous cell
carcinoma [47], and a 20-fold decrease of miR-375 was observed
in oral and pharyngeal squamous cell carcinoma samples
compared with normal control tissues [48]. In contrast, higher
expression of miR-375 has been identified in tumors of prostate
cancer [49], in the sputum of lung adenocarcinoma patients [50],
in the serum of HBV and HBV positive HCC patients [51], and
gastric cancer patients with high risk of recurrence following
surgical resection [52].
Thus, in general miR-9 is associated with cancer progression
while miR-375 is thought to be a cancer suppressor. The previous
findings are consistent with our observations that miR-9 expres-
sion is higher in breast cancer patients with LR. The higher
expression of miR-9 in cancer cells may indicate a more aggressive
tumor, also suggested by the association with higher stage in our
study.
In our study, both miRs were found to be significantly
associated with ER status in breast cancer. Epigenetically
deregulated in breast cancer, miR-375 was previously shown to
form a positive feedback loop with estrogen receptor alpha in
Table 2 miR candidate selection and validation.








Fold Change P value*
miR-643 100% 0.18 0.0008 75% 1.06 0.52
miR-375 97% 0.08 0.0012 100% 0.61 0.29
miR-758 89% 7.40 0.0012 85% 2.91 0.81
miR-573 100% 0.09 0.0028 56% 2.08 0.13
miR-135 b* 61% 29.9 0.0056 85% 0.89 0.59
miR-9 94% 10.6 0.019 100% 1.26 0.0495
miR-190 b 100% 0.11 0.019 98% 1.38 0.80
miR-328 100% 0.11 0.031 96% 0.59 0.35
*p-values were based on Wilcoxon rank sum test.
doi:10.1371/journal.pone.0039011.t002
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39011Figure 1. Association of miR-9 expression levels with breast cancer LR. Delta Ct values of miR-9 are compared between breast cancer
patients with (recurrence status =1) and without (recurrence status =0) breast cancer LR in all tumors (panel A), and in estrogen receptor positive
(panel C) and negative (panel E) tumors. A high delta Ct value indicates a low expression level. ROC curves are drawn to show the capability of miR-9
to discriminate LR in all tumors (panel B), ER positive tumors (panel D) and ER negative tumors (panel F).
doi:10.1371/journal.pone.0039011.g001
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breast cell lines being a key driver of their proliferation [53]. This
is consistent with our observation that miR-375 expression is
higher in ER positive tumors. There has been no report on any
possible link between miR-9 and ER status.
To our knowledge, this is the first study to report on breast
tissue miRs as biomarkers of LR in breast cancer. Several previous
studies have reported the discovery of miRs involved in breast
cancer distant metastasis or being associated with clinico-
pathological characteristics indicative of prognosis [23,26,27,54].
In general, these studies identified prognostic associated miRs that
were not previously found to be involved in breast cancer, possibly
due to differences in experimental procedures or cell specific miRs
that are usually not detected when analyzing whole tumor
samples. In our study, we carefully dissected only tumor cells to
be analyzed, limiting the contamination with stromal and normal
adjacent cells.
In terms of experimental procedure, we used real-time PCR
based methods for both screening and validation. However,
discrepancies in miR measurements between these two steps
could exist because a multiplex mix of primers was used in the
screening while individual primer pairs were used in the
validation. The use of a mixture of primers could induce
potential bias due to competition for template. To monitor the
effect of this factor, we repeated quantification of the 16
screening samples together with the validation samples using
individual real-time PCR assay. Our results indicated that the
delta Ct values of the 16 screening samples in multiplex and
single real-time PCR reactions showed reasonable correlation.
At the same time, the fold changes of miR candidates between
LR cases and non-LR cases in the entire validation sample set
were generally much smaller than those in the screening set
(Table 2). This observation suggests the differences between the
screening and validation results are largely due to the variation
between the screening and validation sample sets rather than
the differences between the assay methods used for screening
and validation. The small sample size of our study could be the
major contributing factor of this variation.
In summary, this study revealed that high expression of miR-9
was significantly associated with an increased risk of breast cancer
LR in patients who were diagnosed with ER positive cancer. We
also found that miR-9 and miR-375 were strongly associated with
ER status of breast tumors. These promising data warrant further
investigation to verify if the expression level of miR-9 in breast
cancer cells can be a useful biomarker, in combination with other




The study was approved by the MedStar Research Institute-
Georgetown University Oncology Institutional Review Board.
The requirements for informed consent from participants were
waived by the Institutional Review Board because all the data and
pathological specimens were previously collected and analyzed
anonymously.
Patient Population
Between 1990 and 2006, a total of 2,025 breast cancer patients
who had informative follow-up data were recorded in the cancer
registry database of the Lombardi Comprehensive Cancer Center
(LCCC). Of these, 1,654 (81.7%) had no disease recurrence at the
last contact (December, 2009), 74 (3.7%) had LR, 200 (9.9%) had
distant recurrence, 45 (2.2%) were never disease free, and 50
(2.5%) had unknown type of recurrence. We included in this study
the 74 patients with LR and randomly selected 148 patients who
had no disease recurrence, matched on year of diagnosis (5-year
interval), type of surgery (total mastectomy, partial mastectomy/
segmental mastectomy, lumpectomy), and age at diagnosis (5-year
interval).
The Clinical Molecular Epidemiology Shared Resources
(CMESR) of the LCCC provided de-identified clinical and
treatment data, including age at diagnosis, date of birth, date of
diagnosis, race, type of surgery, date of surgery, disease stage,
tumor size, radiotherapy and type, radiotherapy date, chemother-
apy and type, chemotherapy date, tumor ER/PR status, re-
currence type, recurrence date, date of first contact, date of last
contact, vital status, date of death. The data were downloaded
from the Cancer Registry of the LCCC and a unique study ID was
assigned to each patient. All patient identifiable information was
Figure 2. Kaplan-Meier survival curves for miR-9. Solid lines
represent LR-free survival curves of breast cancer patients who had miR-
9 low expression tumors in validation sample set, all cases (panel A) and
ER positive cases (panel B). Dotted lines represent the patients who
hadmiR-9 high expression tumors. P values are 0.08 and 0.02 for all
cases (panel A) and ER positive cases (panel B), respectively.
doi:10.1371/journal.pone.0039011.g002
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analysis.
Tumor Tissue Retrieval
Tumor blocks were available and retrieved by the Histopathol-
ogy and Tissue Shared Resources of Lombardi Comprehensive
Cancer Center for 112 (50.5%) of the 222 patients selected for the
study. Eight serial 5-micron and four 20-micron sections were cut
from each block and the first section was H&E stained. One 20-
micron section was used for total RNA isolation. The study
pathologist (BK) examined and marked tumor areas on all H&E
slides. Only 68 tumors containing more than 70% tumor cells
were used for this study. All the tissue sections were labeled with
a unique study ID number.
RNA Isolation and Reverse Transcription
Total RNA was extracted from dissected FFPE breast tissue
samples using the RecoverAll Total Nucleic Acid Isolation Kit
(Ambion, Grand Island, NY) according to the manufacturer’s
instructions. RNA quantity was assessed with the NanoDrop1000
(Thermo Fisher Scientific, Inc., Waltham, MA). The total RNA
yield ranged from 0.12 to 17.27 mg with an average of 2.45 mg.
For each sample, 1 ml total RNA was used for reverse transcription
to create cDNA template for Real-Time PCR using Taqman
Small RNA Assays kit (Applied Biosystems, Carlsbad, CA).




Variables median (IR) P value* median (IR) P value*
Age at diagnosis (years) 0.26 0.69
#50 0.13 (0.05–0.78) 3.54 (1.11–22.86)
.50 0.08 (0.02–0.17) 5.27 (2.07–22.74)
Tumor size (cm) 0.09 0.63
,1.5 0.06 (0.02–0.13) 4.81 (1.89–19.29)
$1.5 0.12 (0.03–0.92) 6.63 (2.07–25.15)
Race 0.07 0.61
White 0.09 (0.02–0.36) 4.88 (1.71–24.04)
Black 0.80 (0.05–1.18) 3.49 (0.18–28.95)
Other 0.08 (0.01–0.18) 8.25 (3.10–24.04)
Histological type 0.41 0.03
Duct carcinoma 0.10 (0.03–0.43) 3.49 (1.42–16.35)
Duct &/or lobular carcinoma 0.05 (0.01–0.17) 6.33 (5.27–8.39)
Others 0.09 (0.06–9.63) 29.44 (28.95–83.15)
Stage, N (%) 0.03 0.62
0 – I 0.10 (0.04–0.44) 7.71 (2.30–23.45)
II 0.08 (0.02–0.20) 4.88 (1.53–9.84)
III – IV 0.82 (0.80–1.17) 3.54 (2.01–26.22)
Type of surgery 0.96 ,0.01
Lumpectomy 0.11 (0.01–1.59) 22.80 (14.53–30.89)
Partial Mastectomy 0.08 (0.06–0.35) 2.07 (0.49–2.96)
Total mastectomy 0.13 (0.05–0.49) 13.09(8.24–22.65)
Others 0.09 (0.02–0.35) 3.59 (1.42–24.04)
Year of Surgery 0.69 0.11
Before 1995 0.10 (0.02–0.17) 2.33 (1.10–2.96)
1995–1999 0.11 (0.06–0.35) 7.53 (2.07–27.56)
After 1999 0.07 (0.04–0.33) 6.63 (3.32–19.54)
Systemic therapy 0.35 0.02
None 0.07 (0.03–0.16) 23.45 (4.76–26.83)
Radiation therapy only 0.17 (0.08–0.78) 6.66 (2.65–14.53)
Chemotherapy only 0.03 (0.01–0.35) 2.58 (1.42–3.59)
Both 0.10 (0.05–0.43) 3.07 (1.03–6.63)
ER‘ status ,0.01 ,0.01
Positive 0.08 (0.02–0.20) 6.63(2.96–25.15)
Negative 0.39 (0.13–1.15) 1.34 (0.22–3.09)
*P values were based on Wilcoxon rank sum test (continuous variables) or Fisher’s exact test (categorical variables) ‘estrogen receptor.
doi:10.1371/journal.pone.0039011.t003
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miR expression profiling was performed using RNA samples
isolated from 16 tumors (8 with LR and 8 with no LR) utilizing the
TaqManArrayHumanMicroRNASetv3.0(AppliedBiosystems)as
described by the manufacturer. For validation, total RNA samples
from tumor tissues of 16 cases with LR and 36 without LR were
isolatedandtheexpressionlevelofindividualmiRwasanalyzedusing
Taqman Small RNA Assays (Applied Biosystems) according to
manufacturer’s instructions. The mean delta Cts of triplicate real-





U6). Ct values of 9 out of the total 544 real-time PCR reactions
(1.7%) were rejected due to a coefficient of variance larger than 5%
among triplicates. Technical staffs that performed the miR assays
were blinded to the recurrence status of the samples.
Statistical Analysis
Wilcoxon rank-sum tests, chi-square, or Fisher’s exact tests were
used to examine the differences between LR and non-LR cases in
continuous and categorical variables, respectively. ROC curves
were generated by plotting sensitivity vs. (1-specificity), and AUC
Figure 3. Association of miR-9 and miR-375 expression levels with tumor estrogen receptor (ER) status. Delta Ct values of miR-9 (panel
A) and miR-375 (panel B) are compared between patients who had ER negative (ER status =0) and ER positive (ER status =1) tumors. A high delta Ct
value indicates a low expression level. The capabilities of miR-9 and miR-375 to discriminate ER status are shown in ROC curves (panel C and D,
respectively).
doi:10.1371/journal.pone.0039011.g003
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each miR in classifying patients into recurrent or non-recurrent
status. Kaplan-Meier analysis for recurrence-free survival was
estimated for patients according to their relative amount of
individual miRs in the tumor tissue and compared using Log-rank
test. Delta Ct values was dichotomized as low/high using the
median value in non-recurrent cases as the cutoff point. P-values
were two-sided and considered significant if p,0.05. All analyses
were performed using SAS software, version 9.3 (SAS Institute,
Inc., Cary, NC).
Supporting Information
Table S1 Correlations among miR candidates.
(DOCX)
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